Securities code: 688046 securities abbreviation: Yaokang biological Announcement No.: 2022011
Jiangsu Jicui Yaokang Biotechnology Co., Ltd
Notes on undisclosed internal control evaluation report in 2021
1、 Construction of internal control system
In accordance with the company law, the securities law and other laws and regulations and the articles of association, the company has established a standardized corporate governance structure composed of the general meeting of shareholders, the board of directors, independent directors, the board of supervisors and senior management. It has established the organizational structure of special committees under the board of directors, such as the audit committee, the strategy committee, the remuneration and assessment committee and the nomination committee, with clear division of responsibilities and mutual cooperation, and formulated corresponding rules of procedure, Clarify the responsibilities and authorities in decision-making, implementation and supervision, and form a scientific and effective division of responsibilities and an effective mechanism of mutual checks and balances. The company comprehensively considers the development strategy, management requirements and other factors, adjusts the internal functional institutions, defines the responsibilities and authorities of each institution, and forms a working mechanism of performing their duties, assuming their responsibilities, mutual restriction and coordination; Establish an internal control system covering all links of the company's business activities and internal management according to the actual situation to control the company's daily operation or management activities. Maintain the safety of the company's assets, prevent and resolve various risks, and improve the company's operation efficiency and management level.
2、 Description of undisclosed annual internal control evaluation report
1. Whether there are special circumstances of non compulsory disclosure
√ yes □ no non mandatory disclosure special circumstances: new listing
2. Specific information: with the approval of the reply on Approving the registration of initial public offering of Jiangsu Jicui Yaokang Biotechnology Co., Ltd. (zjxk [2022] No. 542) issued by China Securities Regulatory Commission, the company publicly issued 50 million RMB common shares (A shares) to the public and was listed on the science and Innovation Board of Shanghai Stock Exchange on April 25, 2022. According to Article 3 (II) of Chapter II of the guidelines for self discipline supervision of listed companies on the science and Innovation Board No. 7 - matters related to annual reports, "a newly listed company shall start building an internal control system in the year of listing, and disclose the internal control evaluation report and internal control audit report at the same time as the annual report of the next year of listing." According to the above relevant provisions, the company is a newly listed company, so the internal control evaluation report of 2021 is not disclosed. The company will disclose the internal control evaluation report while disclosing the annual report of the next year.
Chairman (authorized by the board of directors): Gao Xiang Jiangsu Jicui Yaokang Biotechnology Co., Ltd. May 18, 2022
